COCP 2,09$ (+56%)

Corona-Hype

• Umsatz 0,5 Mio. $ (alles für Q3/19)
  
• Verlust 1,8 Mio. $
  
• Cash 6 Mio. $
  
• MK 87 Mio. $
  

https://www.cocrystalpharma.com/news/...-third-quarter-2019-financial

Dann kam Corona, der Kurs stieg, das Management zog ein Offering durch:

• 3,5 Mio. neue Aktien zu je 0,63$ = 2,2 Mio. $
  

https://www.cocrystalpharma.com/news/...ounces-closing-of-2-2-million

Mal sehen, wann die nächste Kapitalerhöhung kommt...

 

$COCP. Current Report Filing (8-k)

http://ih.advfn.com/stock-market/NASDAQ/.../current-report-filing-8-k

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2020

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)



Delaware 001-38418 35-2528215
(State or other Jurisdiction

of Incorporation)


(Commission

File Number)


(IRS Employer

Identification No.)



19805 N. Creek Parkway

Bothell, WA

98011
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (786) 459-1831


(Former name or former address, if changed since last report.):

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).


§
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common Stock COCP
The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)


Item 7.01 Regulation FD Disclosure.



On March 4, 2020, Cocrystal Pharma, Inc. (the “Company”) posted a presentation to its website. A copy of the Company’s presentation is being furnished as Exhibit 99.1 hereto.



The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, or the Exchange Act.



Item 9.01. Financial Statements and Exhibits.

(d)
Exhibit No.


Description.


99.1 Investor Presentation dated March 2020


SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Cocrystal Pharma, Inc.

Dated: March 4, 2020 By: /s/ James Martin
James Martin
Chief Financial Officer  

March 6, 2020
https://finance.yahoo.com/news/...ounces-plans-advance-210110576.html

... Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development.  

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

http://www.globenewswire.com/news-release/2020/03/...es-for-2020.html  

-50% seit #1  

 

dabei, schauen wir mal wo die Reise hingeht, GLTA.  

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

Cocrystal Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Cocrystal Pharma with a Buy rating and $5 price target. The company utilizes a "unique" proprietary co-crystallization platform to design novel small molecules aimed at well-known molecular targets within multiple viruses, Selvaraju tells investors in a research note. The analyst assumes a partnership to commercialize CC-31244, with royalties of 12%-20% payable to Cocrystal on net sales of the drug.

Read more at:
https://thefly.com/landingPageNews.php?id=3122041  

https://www.marketwatch.com/investing/stock/cocp  

https://www.marketwatch.com/investing/stock/cocp

Riecht nach News, wieder auf das richtige Pferd gesetzt.  

Hallo zusammen,

möglich das es sich um diese Meldung von gestern handelt ?

eurekalert.org/pub_releases/2020-08/ksu-nps080320.php
 

Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

https://www.cocrystalpharma.com/news/...-publication-by-collaborators  

15 Mio. $ Offering

• 14,3 Mio. neue Aktien zu je 1,05$
  

https://seekingalpha.com/news/...a-raises-bought-deal-offering-to-15m

 

https://content.equisolve.net/...stor+Presentation_September+2020.pdf

Denke es hat mit dem TipRanks Artikel zu tun:

Billionaire Steven Cohen Pulls the Trigger on These 2 Penny Stocks

https://finance.yahoo.com/news/...-cohen-pulls-trigger-144600355.html  

https://www.marketwatch.com/investing/stock/cocp  

https://www.marketwatch.com/investing/stock/cocp  

Für einen Freitag ein schöner Endkurs, die Reise geht weiter, imo.  

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

Compound for Further Development Against Coronaviruses

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2

https://www.cocrystalpharma.com/news/...cts-lead-compound-for-further  

https://www.marketwatch.com/investing/stock/cocp  

 

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement


... announces it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now solely responsible for further development of the influenza A/B antiviral compounds that were discovered using Cocrystal’s unique structure-based technologies and Nobel Prize-winning expertise.


... Under the agreement announced in January 2019, Merck had an option for Cocrystal to perform up to 12 months of additional work if the initial two years of collaboration did not progress as expected. We are pleased our collaboration achieved its goals within the timeline and that there is no need for Merck to exercise the option. As this program advances, Merck is now responsible for funding continued development of the compounds.”


... Developing new, effective influenza antivirals represents a significant unmet worldwide medical need and is integral to our infectious diseases R&D strategy,” said Daria Hazuda, Ph.D., Vice President, Infectious Diseases Discovery, Merck Research Laboratories and Chief Scientific Officer, Merck Exploratory Science Center. “We are pleased with the progress under our collaboration with Cocrystal and look forward to further development of the antiviral agents in the influenza A/B program at Merck.”


https://www.cocrystalpharma.com/news/...ther-development-of-influenza
 

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

https://finance.yahoo.com/news/...ma-provides-covid-19-120000496.html